Clinical Trial

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

Study acronym: TATCIST
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The treatment regimen will consist of 4 doses of FPI-2265
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-01-27; most recent amendment 2026-04-02.
Status change: Recruiting → Active, Not Recruiting 2025-02-07
Trial Details
NCT Number NCT05219500
Lead Sponsor Fusion Pharmaceuticals Inc.
Conditions Metastatic Castration Resistant Prostate Cancer
Enrollment 115 participants
Start Date 2021-12-16
Primary Completion 2025-05-30 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-03